RxDoctor Payments Data

Stephen Holloway

Optometrist · Ellwood City, PANPI 1083792618

Payments from drug & device makers

$6,860in general payments, 2019–2025

Across 222 payments — averaging $30.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Vision Care, Inc.$2K
  • Bausch & Lomb Americas Inc.$2K
  • Alcon$589
  • Sun Pharmaceutical Industries Inc.$532
  • Coopervision Inc.$354
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$350
  • plus $839 from 13 others

What the payments were for

  • Consulting fees$1,57723%
  • Food & beverage$5,24476%
  • Gifts$391%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,860 in reported general payments places this provider in the 95th percentile of 2,165 optometrist providers in Pennsylvania.

See all optometrist providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$46,747
Medicare patients
223
Services billed
613

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine39$44,540
Cyclosporine44$30,798
LumiganBimatoprost66$28,141
XiidraLifitegrast14$10,855
RocklatanNetarsudil Mesylat/Latanoprost15$4,751
Fluorometholone23$2,473
Latanoprost191$2,441
Prednisolone Acetate22$1,109
Tobramycin-DexamethasoneTobramycin/Dexamethasone24$940
Timolol Maleate88$691
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat38$497
Brimonidine Tartrate43$429
ErythromycinErythromycin Base33$418
ValacyclovirValacyclovir Hcl11$324
Ofloxacin20$270

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$64$72,681105 claims
Bausch & Lomb Americas Inc.Xiidra$1,904$10,85514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,165 optometrist providers in Pennsylvania.

Other optometrist in Ellwood City

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →